Neurology and Neurosurgery

Episodes 1-16 of 72

• 

  RestartResume

  Team Approach: Enhancing Collaboration in AAD Management

  RestartResume

  Team Approach: Enhancing Collaboration in AAD Management

  MinuteCE®

  Team Approach: Enhancing Collaboration in AAD Management

  1.25 program credits

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  1.25 program credits

• 

  RestartResume

  Innovative Therapeutics: How Pathophysiology Guides New AAD Treatment Development

  RestartResume

  Innovative Therapeutics: How Pathophysiology Guides New AAD Treatment Development

  MinuteCE®

  Innovative Therapeutics: How Pathophysiology Guides New AAD Treatment Development

  1.25 program credits

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  1.25 program credits

• 

  RestartResume

  Proactive Screening: Essential Tools for Diagnosing AAD Quickly

  RestartResume

  Proactive Screening: Essential Tools for Diagnosing AAD Quickly

  MinuteCE®

  Proactive Screening: Essential Tools for Diagnosing AAD Quickly

  1.25 program credits

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  1.25 program credits

• 

  RestartResume

  Building Better Strategies: Incorporating New AAD Treatments Into Clinical Practice

  RestartResume

  Building Better Strategies: Incorporating New AAD Treatments Into Clinical Practice

  MinuteCE®

  Building Better Strategies: Incorporating New AAD Treatments Into Clinical Practice

  1.25 program credits

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  1.25 program credits

• 

  RestartResume

  AAD Treatment Evolution: The Future of Emerging Therapies

  RestartResume

  AAD Treatment Evolution: The Future of Emerging Therapies

  MinuteCE®

  AAD Treatment Evolution: The Future of Emerging Therapies

  1.25 program credits

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  1.25 program credits

• 

  RestartResume

  Burden Beyond the Patient: AAD's Impact on Patients and Caregivers

  RestartResume

  Burden Beyond the Patient: AAD's Impact on Patients and Caregivers

  MinuteCE®

  Burden Beyond the Patient: AAD's Impact on Patients and Caregivers

  1.25 program credits

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  1.25 program credits

• 

  RestartResume

  Early Warning: Clinical Signs of AAD Every PCP and Caregiver Should Know

  RestartResume

  Early Warning: Clinical Signs of AAD Every PCP and Caregiver Should Know

  MinuteCE®

  Early Warning: Clinical Signs of AAD Every PCP and Caregiver Should Know

  1.25 program credits

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  1.25 program credits

• 

  RestartResume

  Mapping the Mind: The Pathophysiology That Drives AAD

  RestartResume

  Mapping the Mind: The Pathophysiology That Drives AAD

  MinuteCE®

  Mapping the Mind: The Pathophysiology That Drives AAD

  1.25 program credits

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  1.25 program credits

• 

  MinuteCE®

  Optimizing Outcomes in AAD in Community PCP and LTC Clinics

  1.25 credits 11 episodes

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  1.25 credits 11 episodes

• 

  RestartResume

  Patient-Centric Approaches to Optimizing Outcomes in AAD: Case Review

  RestartResume

  Patient-Centric Approaches to Optimizing Outcomes in AAD: Case Review

  CME/CE

  Patient-Centric Approaches to Optimizing Outcomes in AAD: Case Review

  0.25 credits

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  0.25 credits

• 

  RestartResume

  Safety, Efficacy, and Black Box Warnings: Challenges Associated With Off-Label Treatments of AAD

  RestartResume

  Safety, Efficacy, and Black Box Warnings: Challenges Associated With Off-Label Treatments of AAD

  MinuteCE®

  Safety, Efficacy, and Black Box Warnings: Challenges Associated With Off-Label Treatments of AAD

  1.25 program credits

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  1.25 program credits

• 

  RestartResume

  Optimizing Outcomes in AAD in Community PCP and LTC Clinics

  RestartResume

  Optimizing Outcomes in AAD in Community PCP and LTC Clinics

  CME/CE

  Optimizing Outcomes in AAD in Community PCP and LTC Clinics

  0.25 credits

  • 

    

    Anton P. Porsteinsson, MD

  0.25 credits

• 

  RestartResume

  Caregiver Screening Tools for Agitation in Alzheimer’s Disease

  RestartResume

  Caregiver Screening Tools for Agitation in Alzheimer’s Disease

  MinuteCE®

  Caregiver Screening Tools for Agitation in Alzheimer’s Disease

  1.25 program credits

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  1.25 program credits

• 

  RestartResume

  Navigating Therapy: Exploring FDA-Approved Treatments for Effective AAD Care

  RestartResume

  Navigating Therapy: Exploring FDA-Approved Treatments for Effective AAD Care

  MinuteCE®

  Navigating Therapy: Exploring FDA-Approved Treatments for Effective AAD Care

  1.25 program credits

  • 

    

    C. Brendan Montano, MD

  • 

    

    Anton P. Porsteinsson, MD

  1.25 program credits

• 

  RestartResume

  Dementia on a Spectrum: Preclinical Stages of MCI in AD

  RestartResume

  Dementia on a Spectrum: Preclinical Stages of MCI in AD

  MinuteCE®

  Dementia on a Spectrum: Preclinical Stages of MCI in AD

  1.00 program credit

  • 

    

    Professor Sir John Hardy

  1.00 program credit

• 

  RestartResume

  Therapeutic Insights: Navigating the Use and Challenges of Disease-Modifying Therapies

  RestartResume

  Therapeutic Insights: Navigating the Use and Challenges of Disease-Modifying Therapies

  MinuteCE®

  Therapeutic Insights: Navigating the Use and Challenges of Disease-Modifying Therapies

  1.00 program credit

  • 

    

    Professor Sir John Hardy

  1.00 program credit